What You Need to Know About Getting Your Weight-Loss Medication

Who Actually Qualifies for a Weight-Loss Prescription

Standard eligibility follows FDA-approved labeling and the 2023 American Association of Clinical Endocrinology (AACE) Obesity Guidelines: a BMI of 30 or above qualifies unconditionally, while a BMI of 27 to 29.9 qualifies when at least one weight-related comorbidity is present. Qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.

BMI Cutoffs and Why They Matter

The BMI cutoff is not arbitrary. The FDA set the 30/27 threshold based on the risk-benefit profile established across the major GLP-1 outcome trials. In STEP-1 (N=1,961), participants had a mean baseline BMI of 37.9 kg/m² and lost a mean 14.9% of body weight on semaglutide 2.4 mg versus 2.4% on placebo at 68 weeks [1]. The trial excluded participants with type 2 diabetes, reinforcing that the drug works across a broad BMI spectrum, not only in people with metabolic disease.

If your BMI falls between 25 and 27, you generally will not qualify for these medications under current FDA labeling, though research into lower-BMI populations is ongoing [2].

Comorbidities That Expand Access

A diagnosis of type 2 diabetes opens additional prescribing pathways. Semaglutide 1 mg (Ozempic) and tirzepatide 5 to 15 mg (Mounjaro) are FDA-approved for glycemic control in type 2 diabetes, and clinicians routinely prescribe them when weight loss is a secondary goal. The SELECT cardiovascular outcomes trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with obesity and established cardiovascular disease but without diabetes (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) [3]. That data led the FDA to add a cardiovascular risk-reduction indication to Wegovy in March 2024.

Age and Exclusion Criteria

Most prescribers require patients to be 18 or older. Wegovy carries an FDA contraindication for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). Active pancreatitis, pregnancy, and severe gastrointestinal disease are also contraindications. Your prescriber will screen for all of these before writing a prescription [4].

The Main Medications Available Right Now

Several prescription weight-loss agents are on the market, but GLP-1 receptor agonists dominate because of their superior efficacy and cardiovascular safety data. Older agents like orlistat and phentermine-topiramate remain available but produce smaller weight losses.

Semaglutide 2.4 mg (Wegovy)

Wegovy is a once-weekly subcutaneous injection approved by the FDA in June 2021 for chronic weight management [4]. The dose is escalated over 16 weeks: starting at 0.25 mg weekly and increasing to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. This slow titration reduces nausea.

STEP-1 (N=1,961) remains the anchor trial. At 68 weeks, 86.4% of semaglutide participants achieved at least 5% weight loss versus 31.5% on placebo. A full 50% achieved at least 15% weight loss, compared to 4.9% on placebo [1].

Tirzepatide 2.5 to 15 mg (Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA for weight management in November 2023 under the brand name Zepbound [5]. The SURMOUNT-1 trial (N=2,539) showed mean weight loss of 20.9% at 72 weeks at the 15 mg dose versus 3.1% on placebo. At the 10 mg dose, mean weight loss was 19.5% [6]. These figures exceed semaglutide's in head-to-head trial data, though direct comparison trials are still limited.

Liraglutide 3 mg (Saxenda)

Saxenda was FDA-approved in 2014 and is a daily injection rather than weekly. The SCALE Obesity and Prediabetes trial (N=3,731) showed 8.0% mean weight loss at 56 weeks versus 2.6% on placebo [7]. Saxenda is generally considered second-line now that weekly agents are available, but it remains an option for patients who have insurance coverage for it when Wegovy or Zepbound are not covered.

Older Oral Agents

Phentermine-topiramate extended-release (Qsymia) and naltrexone-bupropion (Contrave) are FDA-approved oral options. CONQUER (N=2,487) showed phentermine-topiramate 15/92 mg produced 10.2% mean weight loss versus 1.4% on placebo at 56 weeks [8]. These agents have a different side-effect profile, including potential for increased heart rate with phentermine and mood changes with naltrexone-bupropion. They may suit patients who cannot tolerate injections.

How to Actually Get a Prescription

The prescribing process has three main paths: your primary care physician, a specialist (endocrinologist or obesity medicine specialist), or a telehealth platform. Each has different timelines and requirements.

Primary Care and Specialist Routes

Primary care physicians can legally prescribe all FDA-approved weight-loss medications. In practice, appointment wait times of two to six weeks are common in many U.S. Markets. Obesity medicine specialists, who may carry board certification from the American Board of Obesity Medicine (ABOM), often provide more detailed metabolic workups but face even longer wait times in some regions.

The Endocrine Society's 2023 clinical practice guidelines recommend that prescribers conduct a comprehensive medical history, physical examination including BMI and waist circumference, metabolic labs (fasting glucose, HbA1c, lipid panel, thyroid function), and cardiovascular risk assessment before initiating GLP-1 therapy [9].

Telehealth Platforms

Telehealth has dramatically shortened the time from decision to prescription. A synchronous or asynchronous video visit typically produces a prescription decision within one to seven days, with the medication mailed directly or sent to a local pharmacy. Platforms are legally required to follow the same prescribing standards as brick-and-mortar clinics, meaning a licensed clinician must review your labs, history, and consent.

The standard telehealth intake for weight-loss medication typically includes a self-reported health history questionnaire, recent blood pressure reading, BMI calculation from self-reported height and weight, and in many cases a lab order that must be completed before the prescription is finalized.

What Labs Are Usually Required

Most prescribers order a basic metabolic panel and HbA1c before starting. Some add a lipid panel and thyroid-stimulating hormone (TSH). A fasting glucose of 100 to 125 mg/dL (prediabetes range) or an HbA1c of 5.7 to 6.4% actually strengthens the clinical case for GLP-1 therapy, since the STEP-5 trial (N=304) showed sustained 15.2% mean weight loss over 104 weeks in patients with prediabetes [10].

What the Medication Costs and How to Reduce It

Cost is the single largest barrier to access. Branded GLP-1 agents carry a list price of $900 to $1,400 per month in the United States without insurance coverage.

Insurance Coverage

Medicare Part D covers Wegovy for cardiovascular risk reduction following the SELECT trial outcomes and the March 2024 indication expansion [3]. Coverage for purely weight-management indications remains inconsistent across commercial plans. The Treat and Reduce Obesity Act, if passed, would expand Medicare coverage for obesity pharmacotherapy, but as of mid-2025 it has not been enacted.

Employer-sponsored insurance plans vary widely. Checking your formulary under the drug's generic name (semaglutide or tirzepatide) as well as the brand names gives the clearest picture of coverage tier and copay.

Manufacturer Savings Programs

Novo Nordisk offers the Wegovy Savings Card, which can reduce out-of-pocket costs to as low as $0 per month for commercially insured patients who meet income and eligibility criteria. Eli Lilly offers a similar program for Zepbound. These programs do not apply to Medicare or Medicaid beneficiaries.

Compounded Semaglutide

During periods of FDA-designated shortage, compounding pharmacies have been legally permitted to produce semaglutide and tirzepatide. The FDA removed semaglutide from its shortage list in late 2024, which affects the legality of compounded versions. As of mid-2025, prescribers and patients should verify current FDA shortage status before pursuing compounded agents, since the regulatory field has shifted [11].

The HealthRX clinical team uses a three-tier access framework for new patients: Tier 1 patients (BMI 30+, no significant comorbidities, commercially insured) are routed directly to branded GLP-1 prescribing with savings card enrollment. Tier 2 patients (BMI 27 to 29.9, at least one comorbidity, partial or no coverage) receive a prior authorization support workflow and may start with phentermine-topiramate as a bridge. Tier 3 patients (coverage denied, income-limited) are assessed for patient assistance programs and, where legally available, compounded alternatives with enhanced monitoring.

Side Effects: What to Expect and When They Improve

GLP-1 receptor agonists produce a predictable set of gastrointestinal side effects that are directly tied to the dose-escalation schedule. Understanding this helps patients stay on therapy through the initial weeks.

Gastrointestinal Effects

Nausea is the most common side effect, reported by 44% of semaglutide participants in STEP-1 versus 16% on placebo [1]. Vomiting occurs in about 24% of treated patients versus 6% on placebo. Both effects peak during dose escalations and typically improve within one to two weeks of reaching a stable dose.

Constipation affects approximately 24% of semaglutide-treated patients, a higher rate than most patients anticipate. Increasing dietary fiber to 25 to 38 grams per day and water intake to at least 2 liters per day reduces constipation severity in most cases. Diarrhea, though less common than constipation, affects about 30% of tirzepatide-treated patients at peak doses according to SURMOUNT-1 data [6].

Serious but Rare Risks

Acute pancreatitis has been reported in GLP-1 trials. The incidence is low, approximately 0.2% in the semaglutide arm of STEP-1, but the condition is serious. Patients should stop medication and seek immediate care if they develop severe, persistent mid-abdominal pain radiating to the back.

The rodent thyroid tumor signal seen with liraglutide and semaglutide in preclinical studies has not translated to a confirmed human risk in clinical trials, but the boxed warning for medullary thyroid carcinoma remains in FDA labeling [4]. Patients with a personal or family history of MEN2 should not use these drugs.

Muscle Mass Preservation

Weight lost on GLP-1 therapy includes lean mass. A 2023 analysis in the journal Obesity (N=183) found that approximately 25 to 39% of weight lost on semaglutide was lean mass [12]. Resistance training at least two days per week and adequate dietary protein intake (1.2 to 1.6 g/kg of body weight per day, per the International Society of Sports Nutrition position stand) are recommended to limit muscle loss during active weight reduction [13].

What Happens After You Start

The first three months on any GLP-1 agent involve dose escalation, side-effect management, and expectation calibration. Weight loss is rarely dramatic in weeks one through four.

Setting Realistic Timelines

Clinically meaningful weight loss (5% or more of baseline body weight) is typically apparent by week eight to twelve on semaglutide at the 1.0 mg maintenance dose. Full dose of 2.4 mg, with maximum efficacy, is not reached until week 17 at the earliest under the standard titration schedule.

The STEP-5 trial (N=304, 104-week duration) showed that weight loss continued to accrue past 68 weeks, with mean 15.2% reduction at two years versus 2.6% on placebo [10]. This argues against stopping therapy as soon as a goal weight is reached, since the SELECT trial's cardiovascular data also depended on sustained use.

Monitoring During Treatment

Repeat HbA1c and fasting glucose at three months helps detect any glycemic changes. Blood pressure often falls alongside weight loss, which may require adjustment of antihypertensive doses. Gallstone formation risk increases with rapid weight loss on any modality. Patients with a history of gallbladder disease warrant specific counseling, since cholelithiasis occurred in 2.6% of semaglutide-treated patients in STEP-1 versus 1.2% on placebo [1].

Long-Term Discontinuation Risks

Weight regain after stopping GLP-1 therapy is substantial and well-documented. The STEP-4 trial (N=803) showed that participants who discontinued semaglutide after 20 weeks of treatment regained two-thirds of their lost weight by week 68, while those who continued lost an additional 7.9% [14]. This finding has shaped clinical consensus that GLP-1 therapy is a chronic treatment, not a short course.

How to Talk to Your Prescriber

Arriving at a prescribing appointment with specific information accelerates the process. Bring a list of current medications (GLP-1 agents interact with oral medications requiring rapid absorption, such as oral contraceptives and levothyroxine, due to slowed gastric emptying). Bring blood pressure readings from the prior two weeks. Bring any lab results obtained in the past six months.

The Obesity Medicine Association recommends that clinicians use the "5 A's" framework: Ask, Assess, Advise, Agree, and Assist [15]. If your clinician does not discuss behavioral support, nutrition counseling, or follow-up monitoring, you are within your rights to ask explicitly for those components, since the STEP trials paired pharmacotherapy with a reduced-calorie diet and increased physical activity in all participants.

What a Responsible Prescriber Should Tell You

Per the Endocrine Society 2023 guidelines, a responsible prescriber should explain the mechanism of action, the titration schedule, the expected timeline for weight loss, the long-term nature of therapy, the risk of weight regain on discontinuation, contraindications, and the importance of concurrent lifestyle modification [9]. The guidelines state: "Pharmacological therapy for obesity should be used as an adjunct to lifestyle interventions, not as a replacement for them."

Red Flags in the Prescribing Process

Prescribers who offer weight-loss medication without any health history review, without discussing contraindications, or without any follow-up plan are operating outside standard of care. The same applies to platforms that prescribe based solely on a photograph or a number entered into a web form. A legitimate prescriber, whether in person or via telehealth, will ask about your medical history, current medications, and prior weight-loss attempts.

Comparing Your Options at a Glance

| Medication | Dose | Route | Approval Year | Mean Weight Loss (Trial) | |---|---|---|---|---| | Semaglutide (Wegovy) | 2.4 mg weekly | Subcutaneous injection | 2021 | 14.9% at 68 weeks (STEP-1) | | Tirzepatide (Zepbound) | 15 mg weekly | Subcutaneous injection | 2023 | 20.9% at 72 weeks (SURMOUNT-1) | | Liraglutide (Saxenda) | 3 mg daily | Subcutaneous injection | 2014 | 8.0% at 56 weeks (SCALE) | | Phentermine-topiramate ER (Qsymia) | 15/92 mg daily | Oral | 2012 | 10.2% at 56 weeks (CONQUER) | | Naltrexone-bupropion (Contrave) | 32/360 mg daily | Oral | 2014 | 5.0% at 56 weeks (COR-I) |